WELL Health Technologies (WELL.TO) Buy, Sell…

Home

Daily Stock Opinions and Ratings

WELL Health Technologies (WELL.TO)

4.84

-0.21 (4.16%)

as of Jun 5, 2026, 8:00:00 pm Market Open.

298 watching

Investor Insights

Jun 5, 2026, 12:00 am

This summary was created by AI, based on 13 opinions in the last 12 months.

WELL Health Technologies, represented by the symbol WELL-T, is currently navigating a challenging landscape post-pandemic. While it demonstrated strong revenue growth of 56% last quarter, concerns linger regarding its execution and integration of acquisitions. Experts highlight the company's efforts to divest non-core operations in the US, which is seen as a strategic move, but the process is reportedly taking longer than anticipated. The stock has experienced significant volatility, leading some analysts to consider it a speculative investment, albeit at an attractive valuation of around 9-10x PE. Overall, while there is potential for growth particularly in the Canadian market where it holds a small share, investor sentiment is hampered by regulatory scrutiny and past disappointments, creating a tenuous outlook for the stock's future performance.

Consensus

Mixed

Valuation

Undervalued

Similar

Knight, GUD

HOLD

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The fundamental outlook has not changed. Their acquisition from 2021 is still to be proven. Sentiment is shifting towards telehealth with covid being less of a concern. Revenu growth should be good in 2022. The company is moving closer to profitability. Unlock Premium - Try 5i Free

Wealthica Track your Stocks in your Watch List

HOLD

Electronic medical record software. Expectations are very high. Still in growth mode, so not profitable. Street's target is $11, with 60% growth expected next year. Overall, healthcare IT is an interesting space. Lots of competition. A hold. More research required before buying.

BUY ON WEAKNESS

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The entire sector has been weak. Investors have some reservations about dilution from the aggressive acquisition strategy. Still comfortable with the stock in the longer term. Unlock Premium - Try 5i Free

WEAK BUY

With covid, WELL and other tele health came into the spotlight. Their prices appreciated quickly. Now, we are seeing a move away with more competition and the vaccine. In terms of investing, there are better opportunities elsewhere. A good company in an industry that is growing, however.

DON'T BUY

Telehealth player, with more of an unfocused strategy. Whereas AKU is very focused.

BUY ON WEAKNESS

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. No concerns for the stock except for the short term volatility. The short report will affect it short term, but management is committed with no sellers. Insiders own 16%. Attractive around $5.75. Unlock Premium - Try 5i Free

DON'T BUY

He's closely watching the telehealth sector, which leapt ahead years during this pandemic. He prefers Teledoc. WELL is growing by buying businesses and adding customers, but it's a strategy he doesn't like, so he's put WELL on the backburner, but if they integrate these new companies well, WELL will do extremely well.

BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. They are in the midst of acquiring CRH. They will have more than $300M sales. Including expected growth, it looks much cheaper than it is. The company has lost money to date but is expected to make a profit this year. It must execute and is not risk free. Good growth potential. Unlock Premium - Try 5i Free

Wealthica Track your Stocks in your Watch List

DON'T BUY

Canadian success story. Health technology play. A popular stock. Be cautious because of the valuation. Debatable if recent acquisition will be accretive. Trades at 35x forward EBITDA, so quite expensive.

COMMENT

WELL vs. TDOC He likes the industry, especially during Covid. A lot of efficiency gains have been unlocked with telehealth platforms. He prefers TDOC in the US, especially after its recent integration.

HOLD

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The market has shifted quickly recently. However, with an appropriate time frame, this stock should do fine. Nothing has changed fundamentally or at the company level. Though not risk free, the drop is market-related and not fundamental issues with the company. Unlock Premium - Try 5i Free

BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The acquisition of CRH is expected to be highly synergistic. There will be cross selling opportunities and a substantial presence in the US. It will attract new investors as it gets bigger. Unlock Premium - Try 5i Free

BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The US listing is generally positive. The move to be on the US index makes sense for a high growth company. Investors in the US are fine paying up front for future growth. Unlock Premium - Try 5i Free

RISKY

Telehealth will solve some of the problems of escalating health care costs. It's the future. Telus Health is one way to play it. He likes WELL, but not for the faint of heart, big risk/reward. A lot of things have to go right, and you have to assume they'll be cashflow positive in the future. A name you do want to own.

DON'T BUY

Telemedicine is a very hot space, but can't accept the valuations (he's a value investor). They make good acquisitions. Many revenues come from clinics. All tech companies have sky-high valuations, betting on future sales and earnings. Not for the feint of heart. The valuation is too high.

Showing 61 to 75 of 78 entries

Most Recent Experts

Brian Madden

First Avenue Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Virtus Investment Partners

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

WELL Health Technologies (WELL.TO)